GlassScriptPhysician profile
Yoon M Kim
NPI 1134407869
$13,964.29
in general payments reported to CMS, 2019-2025
41 companies · $3,443 in 2025
The $3,443 reported for 2025 was more than what 82% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $1,167 · 2021: $1,949 · 2022: $2,291 · 2023: $2,545 · 2024: $2,154 · 2025: $3,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,127 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,127.17 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,893.60 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,759.80 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,459.65 | 2020-2025 | |
| Amgen INC. | $1,156.57 | 2022-2025 | Tezspire |
| Glaxosmithkline, LLC. | $948.61 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $624.44 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Kaleo, INC. | $528.70 | 2019-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $484.64 | 2019-2025 | |
| Pfizer INC. | $471.76 | 2019-2024 | |
| Abbvie INC. | $400.90 | 2021-2025 | |
| Csl Behring | $368.64 | 2019-2025 | Andembry, Haegarda |
| Biocryst US Sales Co., LLC | $311.10 | 2021-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $252.96 | 2020-2023 | |
| Genentech USA, INC. | $237.70 | 2023-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $217.19 | 2025 | Neffy |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $215.73 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $161.78 | 2019-2025 | Dupixent |
| Aytu Biopharma, INC. | $152.47 | 2022-2025 | Karbinal |
| Covis Pharma Gmbh | $149.96 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.13 | 2020-2022 | |
| Grifols USA, LLC | $118.47 | 2021-2025 | Xembify |
| Hikma Pharmaceuticals USA | $105.36 | 2022-2024 | Ryaltris |
| Mylan Specialty L.P. | $98.19 | 2021-2022 | |
| Galderma Laboratories, L.P. | $87.92 | 2025 | Nemluvio |
| Leo Pharma INC. | $68.22 | 2023-2025 | Adbry |
| Horizon Therapeutics Plc | $65.51 | 2020-2021 | |
| Ionis Pharmaceuticals, INC. | $64.15 | 2025 | Dawnzera |
| Uswm, LLC | $54.12 | 2021 | |
| Shire North American Group INC | $47.48 | 2019 | |
| Lilly USA, LLC | $47.36 | 2025 | Ebglyss |
| Organon LLC | $46.70 | 2025 | Vtama |
| Alk-Abello, INC | $41.06 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Paratek Pharmaceuticals, INC. | $34.60 | 2025 | Xhance, Nuzyra |
| Hospira, INC. | $33.81 | 2020-2022 | |
| Incyte Corporation | $24.13 | 2023 | Opzelura |
| Cycle Pharmaceuticals INC | $23.78 | 2025 | Sajazir |
| Pharming Healthcare, INC. | $22.72 | 2024 | Ruconest |
| Eyevance Pharmaceuticals LLC | $18.26 | 2020 | |
| Viatris Specialty LLC | $14.49 | 2025 | Yupelri |
| Phadia US INC. | $13.92 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $13.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoon Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.